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Technological and analytical advances have led to an unprecedented catalog of genomic regions
associated with a broad range of clinically relevant phenotypes in humans. However, some
examples notwithstanding, the causes of the overwhelming majority of genetic diseases remain
obscure. More importantly, an emerging lesson from genome-wide association studies is that, in
most instances, the resolution necessary for identifying actual genes that underlie the phenotype is
limited, as is our ability to develop mechanistic, testable disease models from such studies. These
new realities will probably necessitate a paradigm shift in our approach to complex traits, for which
the combinatorial application of genomic and functional studies will be necessary to understand the
mechanism and pathology of genetic disease. Here I will discuss these issues and highlight how
additional sequencing and genotyping of ever-increasing cohort sizes without functional
interpretation is unlikely to improve our ability to dissect the genetic basis of complex traits.
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The sequencing of several genomes and the HapMap project,
coupled to high-density genotyping technologies and new
statistical tools, have made possible the systematic interro-
gation of the genetic basis of complex traits in humans [1,2].
Largely consistent with the community’s expectations, the
past two years have seen a logarithmically expanding
number of genomic regions associated with a broad range of
phenotypes (see [3] for an updated list). We now know of at
least 16 potential susceptibility loci for type 2 diabetes in the
human genome [4], and there are similar or better numbers
for other diseases, including type 1 diabetes (24+ loci) and
Crohn’s disease (30+ loci; see [5,6] for examples). Similar
progress has been made in the identification of genomic
regions that influence quantitative traits, such as height [7],
metabolite abundance [8] and drug response [9].
These discoveries infuse us with optimism about the
potential for understanding the key homeostatic pathways
that are causally related to these disorders, which could lead
to new drug development and better patient management.
At the same time, these studies have presented us with some
surprising findings. Most importantly, lost in the collective
euphoria of apparently rapid progress is the fact that, some
notable exceptions notwithstanding, we are now faced with
three major challenges. Firstly, the total sum of disease risk
attributed to common variants detected by genome-wide
association studies (GWASs) remains modest, raising a
problem analogous to the astrophysicists’ search for ‘dark
matter’. Secondly, the overwhelming majority of single
nucleotide polymorphisms (SNPs) associated with disease
lie in intra- or intergenic regions; there has been a striking
dearth of coding SNPs. Finally, almost none of the asso-
ciation studies have led to the identification of the causal
allele(s), and thus neither the ‘disease-associated’ gene, nor
indeed the type of lesion (gain-of-function, loss-of-function,
and so on), can be identified unequivocally. The sheer
number of disorders subjected to GWAS suggests that these
deficiencies are unlikely to be random findings, or to
represent idiosyncratic genetic architecture of specific
phenotypes. Rather, it is likely that these observations result
from biological principles that will require a significant shift
in our approach to understand them.The second challenge, that of the modest risk conferred by
common variants, is in some ways a minor problem, despite
the unwelcome consequence that it potentially hinders, and
might even defeat, the utility of high-density genotyping as a
prognostic clinical tool. The fact that the relative risk con-
ferred by most SNPs associated with Crohn’s disease lingers
in the 1.2-1.5 range (with the exception of alleles of NOD2,
which encodes nucleotide oligomerization domain protein 2,
and IL23R, which encodes the interleukin-23 receptor) does
not detract from the establishment of the hypothesis that
defective autophagy is part of the cause of this disorder [10],
which has, in turn, enabled the development of mammalian
models to study the disease process [11,12]. Likewise, the
association of the same genomic regions with discrete dis-
orders can highlight not only suspected relationships (rheuma-
toid arthritis and lupus), but also novel and surprising ones
(diabetes and colon cancer; see [1] for more details).
The first and third challenges mentioned above, those of the
genetic ‘dark matter’ and allele causality (coupled to mutational
models), are more complex and are probably interlinked.
Reasonable hypotheses have been put forth that suggest that
the failure to detect the majority of the genetic load in complex
disease is a reflection of insufficient statistical power, as
evidenced by the accelerated locus discovery by meta-analyses.
At the same time, evolutionary arguments have been proposed
to explain the preferential enrichment of non-coding variants
in complex disease. Most prominently, it has been suggested
that strong (often coding) mutations that have a significant
impact on fitness would be more likely to be associated with
Mendelian disorders, whereas milder alleles that affect
spatiotemporal patterns of gene expression are more likely
candidates for exerting modest effects in complex disease [13].
It is reasonable to predict that understanding of the total
genetic load in complex disease will be enhanced by higher
density genotyping, increased sample size and expanded
ethnic diversity, and medical resequencing of risk regions.
Importantly, however, none of these tools will unequivocally
enable the transition from association to causality.
The sobering reality remains that, despite the hundreds of
loci identified, the number of bona fide genes associated
with complex disease identified through GWASs is modest.
Regrettably, a guilty-by-association view has emerged and
the definitions of ‘locus’ and ‘gene’ are becoming danger-
ously interchangeable. At best, most arguments for the role
of specific genes on conferring susceptibility put forth to
date are correlative; although many will turn out to be
correct, this is unlikely to be the ubiquitous truth. Recent
work in age-related macular degeneration (AMD) highlights
the problem. Case-control association studies pointed to a
region on 10q26 that conferred strong susceptibility to AMD,
and further work suggested that variation in the promoter
region of HTRA1, which encodes a multi-functional serine
protease, might explain the effect [14]. However, additional
genotyping [15] and, independently, complete resequencing of
the risk haplotype, pointed to a deletion in the 3’ untranslated
region (UTR) of predicted transcript LOC387715 that
destabilizes its message, suggesting that loss of that
transcript, and not HTRA1, drives the susceptibility to AMD
[16]. Unfortunately, the presence of a haplotype that is not
associated with AMD that carries a premature termination
codon in LOC387715 confounds that hypothesis as well [17].
Similar questions should be raised about the direct involve-
ment in obesity of the FTO gene, given that the associated
SNP lies in intron 1 of that gene’s transcript [18]. Even
though the FTO protein is now being investigated mecha-
nistically to understand energy regulation [19], there is no
actual evidence that FTO is the gene that underlies the
association. Notably, FTO, and the neighboring gene FTM
(or  RPGRIP1L), which lies less than 1 kilobase away in a
head-to-tail orientation, have been shown to be co-regulated
by the transcription factor CUTL1, and at least one of the
associated SNPs maps to a predicted CUTL1 binding site
[20], raising the possibility that dysfunction at FTM, not
FTO, might be the driver of the phenotype. Intriguingly, FTM
is mutated in several ciliopathies, which are hallmarked,
among other features, by hyperphagia-driven obesity [21].
There is no doubt that additional, denser genotyping, ad-
mixture mapping and deep resequencing will refine current
loci and uncover new ones. However, it is important to
consider the relative value of these data without physio-
logically relevant functional interpretation. In some instances,
population- and genetic-based arguments can suggest that
certain alleles cause certain phenotypes, as has been shown by
medical resequencing of candidate genes in patients at the
extremes of high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) plasma levels [22,23]. Nonetheless, even in
these examples, in vitro assays that tested the functional
consequences of the mutations were necessary for the
researchers to present compelling arguments.
Given these observations, it might be prudent to refocus our
efforts on how to evaluate the physiological impact of genetic
and genomic variation on gene function, because without
that ability, the contribution of additional GWASs on under-
standing disease mechanisms will remain limited. Given the
plethora of in vitro and  in vivo tools available to the
community, it should be possible to develop assays that can
test directly the effect of gene variation in appropriate cell
lines, cell types and animal models; without such tools, we
might be left with an unexplorable catalog of associated
SNPs but gain little wisdom about how to develop diag-
nostics and therapeutics for complex traits.
A Ab bb br re ev vi ia at ti io on ns s
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wide association study; SNP, single nucleotide polymorphism.
http://genomemedicine.com/content/1/2/23 Genome Medicine 2009, Volume 1, Issue 2, Article 23 Katsanis 23.2
Genome Medicine 2009, 1 1: :23C Co om mp pe et ti in ng g   i in nt te er re es st ts s
The author has no competing interests to declare.
A Ac ck kn no ow wl le ed dg ge em me en nt ts s
I thank Sara Katsanis and Erica Davis for helpful discussion and editing of
the manuscript. This work was supported by grants R01HD04260 from
the National Institute of Child Health and Development, R01DK072301
and R01DK075972 from the National Institute of Diabetes, Digestive, and
Kidney disorders and P20MH084018 from the National Institute of Mental
Health.
R Re ef fe er re en nc ce es s
1. Altshuler D, Daly MJ, Lander ES: G Ge en ne et ti ic c   m ma ap pp pi in ng g   i in n   h hu um ma an n   d di is se ea as se e. .
Science 2008, 3 32 22 2: :881-888.
2. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioan-
nidis JPA, Hirschhorn JN: G Ge en no om me e- -w wi id de e    a as ss so oc ci ia at ti io on n    s st tu ud di ie es s    f fo or r
c co om mp pl le ex x    t tr ra ai it ts s: :    c co on ns se en ns su us s, ,    u un nc ce er rt ta ai in nt ty y    a an nd d    c ch ha al ll le en ng ge es s. . Nat Rev
Genet 2008, 9 9: :356-369.
3. A A    C Ca at ta al lo og g    o of f    P Pu ub bl li is sh he ed d    G Ge en no om me e- -w wi id de e    A As ss so oc ci ia at ti io on n    S St tu ud di ie es s
[http://www.genome.gov/26525384]
4. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker
PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Boström KB,
Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H,
Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL,
Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert
H, Grarup N, et al.: M Me et ta a- -a an na al ly ys si is s   o of f   g ge en no om me e- -w wi id de e   a as ss so oc ci ia at ti io on n   d da at ta a
a an nd d   l la ar rg ge e- -s sc ca al le e   r re ep pl li ic ca at ti io on n   i id de en nt ti if fi ie es s   a ad dd di it ti io on na al l   s su us sc ce ep pt ti ib bi il li it ty y   l lo oc ci i   f fo or r
t ty yp pe e   2 2   d di ia ab be et te es s. . Nat Genet 2008, 4 40 0: :638-645.
5. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD,
Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Das-
sopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha
MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR,
Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C,
Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, et al.: G Ge en no om me e- -w wi id de e
a as ss so oc ci ia at ti io on n    d de ef fi in ne es s    m mo or re e    t th ha an n    3 30 0    d di is st ti in nc ct t    s su us sc ce ep pt ti ib bi il li it ty y    l lo oc ci i    f fo or r
C Cr ro oh hn n’ ’s s   d di is se ea as se e. . Nat Genet 2008, 4 40 0: :955-962.
6. Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, Allen JE,
Downes K, Barrett JC, Healy BC, Mychaleckyj JC, Warram JH, Todd
JA:  M Me et ta a- -a an na al ly ys si is s    o of f    g ge en no om me e- -w wi id de e    a as ss so oc ci ia at ti io on n    s st tu ud dy y    d da at ta a    i id de en nt ti if fi ie es s
a ad dd di it ti io on na al l   t ty yp pe e   1 1   d di ia ab be et te es s   r ri is sk k   l lo oc ci i. . Nat Genet 2008, 4 40 0: :1399-1401.
7. Gudbjartsson DF, Walters GB, Thorleifsson G, Stefansson H, Hall-
dorsson BV, Zusmanovich P, Sulem P, Thorlacius S, Gylfason A,
Steinberg S, Helgadottir A, Ingason A, Steinthorsdottir V, Olafsdottir
EJ, Olafsdottir GH, Jonsson T, Borch-Johnsen K, Hansen T, Ander-
sen G, Jorgensen T, Pedersen O, Aben KK, Witjes JA, Swinkels DW,
den Heijer M, Franke B, Verbeek AL, Becker DM, Yanek LR, Becker
LC, et al.: M Ma an ny y   s se eq qu ue en nc ce e   v va ar ri ia an nt ts s   a af ff fe ec ct ti in ng g   d di iv ve er rs si it ty y   o of f   a ad du ul lt t   h hu um ma an n
h he ei ig gh ht t. . Nat Genet 2008, 4 40 0: :609-615.
8. Hazra A, Kraft P, Selhub J, Giovannucci EL, Thomas G, Hoover RN,
Chanock SJ, Hunter DJ: C Co om mm mo on n   v va ar ri ia an nt ts s   o of f   F FU UT T2 2   a ar re e   a as ss so oc ci ia at te ed d
w wi it th h   p pl la as sm ma a   v vi it ta am mi in n   B B1 12 2   l le ev ve el ls s. . Nat Genet 2008, 4 40 0: :1160-1162.
9. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz
UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie
AE, Rieder MJ: A A   g ge en no om me e- -w wi id de e   s sc ca an n   f fo or r   c co om mm mo on n   g ge en ne et ti ic c   v va ar ri ia an nt ts s
w wi it th h   a a   l la ar rg ge e   i in nf fl lu ue en nc ce e   o on n   w wa ar rf fa ar ri in n   m ma ai in nt te en na an nc ce e   d do os se e. .   Blood 2008,
1 11 12 2: :1022-1027.
10. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A,
Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths
AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro
M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ,
Brant SR: G Ge en no om me e- -w wi id de e   a as ss so oc ci ia at ti io on n   s st tu ud dy y   i id de en nt ti if fi ie es s   n ne ew w   s su us sc ce ep pt ti ib bi il l- -
i it ty y   l lo oc ci i   f fo or r   C Cr ro oh hn n   d di is se ea as se e   a an nd d   i im mp pl li ic ca at te es s   a au ut to op ph ha ag gy y   i in n   d di is se ea as se e   p pa at th ho o- -
g ge en ne es si is s. . Nat Genet 2007, 3 39 9: :596-604.
11. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C,
Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleck-
man BP, Li E, Mizushima N, Stappenbeck TS, Virgin HW 4th: A A   k ke ey y
r ro ol le e   f fo or r   a au ut to op ph ha ag gy y   a an nd d   t th he e   a au ut to op ph ha ag gy y   g ge en ne e   A At tg g1 16 6l l1 1   i in n   m mo ou us se e   a an nd d
h hu um ma an n   i in nt te es st ti in na al l   P Pa an ne et th h   c ce el ll ls s. . Nature 2008, 4 45 56 6: :259-263.
12. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang B-G, Satoh T, Omori
H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsu-
jimura T, Takeuchi O, Yoshimori T, Akira S: L Lo os ss s   o of f   t th he e   a au ut to op ph ha ag gy y
p pr ro ot te ei in n   A At tg g1 16 6L L1 1   e en nh ha an nc ce es s   e en nd do ot to ox xi in n- -i in nd du uc ce ed d   I IL L- -1 1[ [b bg gr r] ]   p pr ro od du uc ct ti io on n. .
Nature 2008, 4 45 56 6: :264-268.
13. Reich DE, Lander ES: O On n    t th he e    a al ll le el li ic c    s sp pe ec ct tr ru um m    o of f    h hu um ma an n    d di is se ea as se e. .
Trends Genet 2001, 1 17 7: :502-510.
14. Marx J: G Ge en ne e   o of ff fe er rs s   i in ns si ig gh ht t   i in nt to o   m ma ac cu ul la ar r   d de eg ge en ne er ra at ti io on n. .   Science 2006,
3 31 14 4: :405.
15. Kanda A, Chen W, Othman M, Branham KEH, Brooks M, Khanna R,
He S, Lyons R, Abecasis GR, Swaroop A: A A   v va ar ri ia an nt t   o of f   m mi it to oc ch ho on nd dr ri ia al l
p pr ro ot te ei in n   L LO OC C3 38 87 77 71 15 5/ /A AR RM MS S2 2, ,   n no ot t   H HT TR RA A1 1, ,   i is s   s st tr ro on ng gl ly y   a as ss so oc ci ia at te ed d   w wi it th h
a ag ge e- -r re el la at te ed d    m ma ac cu ul la ar r    d de eg ge en ne er ra at ti io on n. .    Proc Natl Acad Sci USA 2007,
1 10 04 4: :16227-16232.
16. Fritsche LG, Loenhardt T, Janssen A, Fisher SA, Rivera A, Keilhauer
CN, Weber BHF: A Ag ge e- -r re el la at te ed d    m ma ac cu ul la ar r    d de eg ge en ne er ra at ti io on n    i is s    a as ss so oc ci ia at te ed d
w wi it th h    a an n    u un ns st ta ab bl le e    A AR RM MS S2 2    ( (L LO OC C3 38 87 77 71 15 5) )    m mR RN NA A. . Nat Genet 2008,
4 40 0: :892-896.
17. Allikmets R, Dean M: B Br ri in ng gi in ng g   a ag ge e- -r re el la at te ed d   m ma ac cu ul la ar r   d de eg ge en ne er ra at ti io on n   i in nt to o
f fo oc cu us s. . Nat Genet 2008, 4 40 0: :820-821.
18. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lind-
gren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B,
Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM,
Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, Jarvelin
MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I,
Wareham NJ, et al.: A A   c co om mm mo on n   v va ar ri ia an nt t   i in n   t th he e   F FT TO O g ge en ne e   i is s   a as ss so oc ci ia at te ed d
w wi it th h    b bo od dy y    m ma as ss s    i in nd de ex x    a an nd d    p pr re ed di is sp po os se es s    t to o    c ch hi il ld dh ho oo od d    a an nd d    a ad du ul lt t
o ob be es si it ty y. .   Science 2007, 3 31 16 6: :889-894.
19. Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, Hewitson KS,
Yeo GS, McDonough MA, Cunliffe S, McNeill LA, Galvanovskis J,
Rorsman P, Robins P, Prieur X, Coll AP, Ma M, Jovanovic Z, Farooqi
IS, Sedgwick B, Barroso I, Lindahl T, Ponting CP, Ashcroft FM,
O’Rahilly S, Schofield CJ: T Th he e   o ob be es si it ty y- -a as ss so oc ci ia at te ed d   F FT TO O   g ge en ne e   e en nc co od de es s
a a   2 2- -o ox xo og gl lu ut ta ar ra at te e- -d de ep pe en nd de en nt t   n nu uc cl le ei ic c   a ac ci id d   d de em me et th hy yl la as se e. .   Science 2007,
3 31 18 8: :1469-1472.
20. Stratigopoulos G, Padilla SL, LeDuc CA, Watson E, Hattersley AT,
McCarthy MI, Zeltser LM, Chung WK, Leibel RL: R Re eg gu ul la at ti io on n    o of f
F Ft to o/ /F Ft tm m   g ge en ne e   e ex xp pr re es ss si io on n   i in n   m mi ic ce e   a an nd d   h hu um ma an ns s. .   Am J Physiol Regul
Integr Comp Physiol 2008, 2 29 94 4: :R1185-R1196.
21. Badano JL, Mitsuma N, Beales PL, Katsanis N: T Th he e   c ci il li io op pa at th hi ie es s: :   a an n
e em me er rg gi in ng g    c cl la as ss s    o of f    h hu um ma an n    g ge en ne et ti ic c    d di is so or rd de er rs s. .    Annu Rev Genomics
Hum Genet 2006, 7 7: :125-148.
22. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs
HH: M Mu ul lt ti ip pl le e   r ra ar re e   a al ll le el le es s   c co on nt tr ri ib bu ut te e   t to o   l lo ow w   p pl la as sm ma a   l le ev ve el ls s   o of f   H HD DL L
c ch ho ol le es st te er ro ol l. . Science 2004, 3 30 05 5: :869-872.
23. Kotowski IK, Pertsemlidis A, Luke A, Cooper RS, Vega GL, Cohen
JC, Hobbs HH: A A   s sp pe ec ct tr ru um m   o of f   P PC CA AK K9 9 a al ll le el le es s   c co on nt tr ri ib bu ut te es s   t to o   p pl la as sm ma a
l le ev ve el ls s   o of f   l lo ow w- -d de en ns si it ty y   l li ip po op pr ro ot te ei in n   c ch ho ol le es st te er ro ol l. .   Am J Hum Genet 2006,
7 78 8: :410-422.
http://genomemedicine.com/content/1/2/23 Genome Medicine 2009, Volume 1, Issue 2, Article N2 23 3 Katsanis 23.3
Genome Medicine 2009, 1 1: :23